Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.12692
Abstract: Many drug labels contain information on pharmacogenomic biomarkers (PGBMs), but the information is not necessarily actionable. Pharmacogenomics Knowledgebase (PharmGKB) aims to clarify the level of action for PGBMs (PGx levels) implied in each label as… read more here.
Keywords: information; drug labels; pharmacogenomic biomarkers; biomarkers interpretation ... See more keywords
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835919846421
Abstract: Background: Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line RAS wild-type and the prediction of individual limiting toxicity syndromes (LTS)… read more here.
Keywords: fir fox; ras wild; pharmacogenomic biomarkers; triplet ... See more keywords
Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation
Sign Up to like & getrecommendations! Published in 2019 at "Genes"
DOI: 10.3390/genes10080599
Abstract: Prostate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate cancer, the high inter-individual variability of… read more here.
Keywords: cancer; pharmacogenomic biomarkers; docetaxel treatment; prostate cancer ... See more keywords